Low HDL causes: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) |
|||
| Line 18: | Line 18: | ||
{|style="width:80%; height:100px" border="1" | {|style="width:80%; height:100px" border="1" | ||
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular''' | |style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular''' | ||
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | | |style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | [[Abdominal aortic aneurysm]], apo A-1 Giessen, apo A-1 Marburg, [[apo A-1 Milano]], apo A-1 Munster, [[apolipoprotein C2|apolipoprotein C-11 deficiency]], [[coronary heart disease]], [[cholesterylester transfer protein|elevated cholesterylester transfer protein (CETP) activity]], [[familial hypoalphalipoproteinemia|familial apo A-1 deficiency]], familial combined hypolipidemia, familial deficiency of apo A-1 and apo C-111, [[familial HDL deficiency]], [[familial hypertriglyceridaemia]], [[familial hypoalphalipoproteinemia]], [[lecithin cholesterol acyltransferase deficiency|familial lecithin-cholesterol acyltransferase (LCAT) deficiency]], [[familial mixed hyperlipidaemia]], [[triglyceride|high triglyceride]], [[LDL receptor deficiency]], [[lipoprotein lipase deficiency]], [[metabolic syndrome]], [[reaven syndrome|Reaven syndrome X]], [[diabetes mellitus|uncontrolled diabetes mellitus]] | ||
|- | |- | ||
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning''' | |bgcolor="LightSteelBlue"| '''Chemical/Poisoning''' | ||
| Line 33: | Line 33: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Drug Side Effect''' | | '''Drug Side Effect''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Anabolic steroids]], [[androgens]], [[atazanavir|atazanavir sulfate]], [[atenolol]], [[bendrofluazide]], [[benzodiazepines]], [[beta blockers]], [[hydrochlorothiazide]], [[lopinavir]], [[probucol]], [[progestins]], [[propranolol]], [[thiazide diuretics]], [[tibolone]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| Line 41: | Line 41: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Endocrine''' | | '''Endocrine''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Insulin resistance]], [[metabolic syndrome]], [[reaven syndrome|Reaven syndrome X]], [[diabetes mellitus|uncontrolled diabetes mellitus]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| Line 49: | Line 49: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Gastroenterologic''' | | '''Gastroenterologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Severe liver disease]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Genetic''' | | '''Genetic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[cholesterylester transfer protein|Elevated cholesterylester transfer protein (CETP) activity]], [[hepatic lipase|elevated hepatic triglyceride lipase activity]], [[familial hypoalphalipoproteinemia|familial apo A-1 deficiency]], familial combined hypolipidemia, familial deficiency of apo A-1 and apo C-111, [[familial HDL deficiency]], [[familial hypertriglyceridaemia]], [[familial hypoalphalipoproteinemia]], [[lecithin-cholesterol acyltransferase|familial lecithin-cholesterol acyltransferase (LCAT) deficiency]], [[familial mixed hyperlipidaemia]], [[fish eye disease|Fish eye disease (partial LCAT deficiency)]], [[LDL receptor deficiency]], [[lipoprotein lipase deficiency]], [[metabolic syndrome]], [[Niemann-Pick disease|Niemann-Pick disease type B]], [[reaven syndrome|Reaven syndrome X]], [[sphingomyelinase deficiency]], [[Tangier disease]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| Line 73: | Line 73: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Neurologic''' | | '''Neurologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Niemann-Pick disease type B]], [[sphingomyelinase deficiency]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Nutritional/Metabolic''' | | '''Nutritional/Metabolic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[carbohydrate|High carbohydrate diet]], [[triglyceride|High triglyceride]], [[malabsorption]], [[malnutrition]], [[metabolic syndrome]], [[obesity]], [[reaven syndrome|Reaven syndrome X]], [[low-fat diet|Very low-fat diet]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| Line 89: | Line 89: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Ophthalmologic''' | | '''Ophthalmologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[fish eye disease|Fish eye disease (partial LCAT deficiency)]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| Line 105: | Line 105: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Renal/Electrolyte''' | | '''Renal/Electrolyte''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Chronic renal failure]], [[end-stage renal disease]], [[nephrotic syndrome]], [[diabetes mellitus|uncontrolled diabetes mellitus]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Rheumatology/Immunology/Allergy''' | | '''Rheumatology/Immunology/Allergy''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| Dysglobulinemia, [[gammopathy|gammopathies]], [[inflammatory disease|severe inflammatory disease]], [[metabolic syndrome]], [[reaven syndrome|Reaven syndrome X]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| Line 125: | Line 125: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Miscellaneous''' | | '''Miscellaneous''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Physical inactivity]], [[smoking]] | ||
|- | |- | ||
|} | |} | ||
Revision as of 17:02, 24 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Low HDL causes On the Web |
|
American Roentgen Ray Society Images of Low HDL causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]
Overview
Low high-density lipoprotein (HDL) may be caused by familial or primary and secondary conditions or disorders associated with decreased levels of HDL in plasma.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Causes by Organ System
Causes in Alphabetical Order
References
- ↑ Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T (2010). "Serum high-density and low-density lipoprotein cholesterol is associated with abdominal aortic aneurysm presence: a systematic review and meta-analysis". Int Angiol. 29 (4): 371–5. PMID 20671656.
- ↑ Achar S, Rostamian A, Narayan SM (2010). "Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm". Am J Cardiol. 106 (6): 893–901. doi:10.1016/j.amjcard.2010.05.013. PMID 20816133.
- ↑ Baggio, G; Manzato, E; Gabelli, C; Fellin, R; Martini, S; Enzi, G B; Verlato, F; Baiocchi, M R; Sprecher, D L; Kashyap, M L (1986). "Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients". Journal of Clinical Investigation. 77 (2): 520–527. doi:10.1172/JCI112332. ISSN 0021-9738.
- ↑ Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T; et al. (2011). "Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region". Circulation. 124 (19): 2056–64. doi:10.1161/CIRCULATIONAHA.111.028373. PMID 21986289.
- ↑ Cuisinier-Raynal JC, Bire F, Clerc M, Bernard J, Sarrouy J (1990). "[Human malaria: dysglobulinemia-hypocholesterolemia syndrome]". Med Trop (Mars). 50 (1): 91–5. PMID 2366654.
- ↑ Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C; et al. (2010). "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia". N Engl J Med. 363 (23): 2220–7. doi:10.1056/NEJMoa1002926. PMC 3008575. PMID 20942659.
- ↑ Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS; et al. (1985). "Familial apolipoprotein A-I and C-III deficiency, variant II". J Lipid Res. 26 (9): 1089–101. PMID 3934306.
- ↑ Ito MK (2004). "The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin". Ann Pharmacother. 38 (2): 277–85. doi:10.1345/aph.1D218. PMID 14742767.
- ↑ 9.0 9.1 9.2 Ashen, M. Dominique; Blumenthal, Roger S. (2005). "Low HDL Cholesterol Levels". New England Journal of Medicine. 353 (12): 1252–1260. doi:10.1056/NEJMcp044370. ISSN 0028-4793.
- ↑ Yamashita S, Matsuzawa Y (2009). "Where are we with probucol: a new life for an old drug?". Atherosclerosis. 207 (1): 16–23. doi:10.1016/j.atherosclerosis.2009.04.002. PMID 19457483.
- ↑ Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J (2004). "Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C". Curr Med Res Opin. 20 (7): 1087–94. doi:10.1185/030079904125004105. PMID 15265253.